Phaseline

Targets › SLC12A2

SLC12A2 (Solute carrier family 12 member 2): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 1; Cardiovascular, Other; next expected readout Nov 2026.

Cation-chloride cotransporter which mediates the electroneutral transport of chloride, potassium and/or sodium ions across the membrane. Plays a vital role in the regulation of ionic balance and cell volume. (UniProt, P55011)

Open in Phaseline: the race on SLC12A2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of FloridaLasix ONYU
Loop diuretic (furosemide)
SLC12A2Phase 4Heart FailureNov 2026
Berlin-Chemie AG Menarini GroupTorasemide tablet 10 mg
Loop diuretic - inhibits Na-K-2Cl cotransporter
SLC12A2Phase 1Healthy Adult Male and Female Volunteers–

Conditions

Heart Failure (1) Healthy Adult Male and Female Volunteers (1)

Modalities

small molecule (2)

Companies

University of Florida (1) Berlin-Chemie AG Menarini Group (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.